Comparison of the risk of pneumothorax in COVID-19 and seasonal influenza.

Publication date: Sep 10, 2024

Limited evidence exists regarding the link between coronavirus disease 2019 (COVID-19) and pneumothorax. Therefore, we aimed to evaluate the occurrence rate of pneumothorax in hospitalized patients with COVID-19 and compare the risk of pneumothorax between patients with COVID-19 and influenza. This retrospective cohort study used patient data from the National Health Insurance Service of South Korea. Patients diagnosed with COVID-19 (December 2019 to December 2021) and influenza (January 2019 to December 2021) who required hospitalization and respiratory support were included. We identified 46,460 patients with COVID-19 and 6,117 with influenza. The occurrence rate of pneumothorax was 0. 74% in patients with COVID-19. In an inverse probability of treatment weighting matched cohort, the Cox proportional hazards regression model showed that COVID-19 was not associated with an increased risk of pneumothorax compared to influenza (hazard ratio, 1. 22; 95% confidence interval, 0. 75-1. 99). However, the risk of pneumothorax associated with COVID-19 compared to influenza was significantly higher in patients without chronic lung disease than in those with (P for heterogeneity = 0. 037). In conclusion, COVID-19, compared with influenza, is not associated with an increased risk of pneumothorax; however, it is associated with an increased risk in patients without chronic lung disease.

Open Access PDF

Concepts Keywords
Coronavirus Adult
December Aged
Korea Aged, 80 and over
Chronic lung disease
COVID-19
COVID-19
Female
Hospitalization
Humans
Influenza
Influenza, Human
Male
Middle Aged
Pneumonia
Pneumothorax
Pneumothorax
Proportional Hazards Models
Republic of Korea
Retrospective Studies
Risk Factors
SARS-CoV-2
Seasons
Young Adult

Semantics

Type Source Name
disease MESH pneumothorax
disease MESH COVID-19
disease MESH influenza
disease MESH lung disease
drug DRUGBANK Coenzyme M
disease MESH Pneumonia
drug DRUGBANK Medical air
disease MESH COPD
disease MESH emphysema
disease MESH infections
disease IDO susceptibility
drug DRUGBANK Oxygen
drug DRUGBANK Isoxaflutole
disease MESH comorbidity
drug DRUGBANK Trestolone
pathway KEGG Coronavirus disease
disease MESH Hypertension
disease MESH Myocardial infarction
disease MESH Congestive heart failure

Original Article

(Visited 7 times, 1 visits today)